Ascensia Diabetes Care has announced that Whisk, the world’s smartest food platform, has been selected as the winner of the global Ascensia Diabetes Challenge during the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL.
Whisk’s smart food platform creates smarter food experiences that help users make healthy, informed decisions by enabling them to select recipes based on the many factors that influence behaviour, including their personal taste preferences, time constraints, budgets and dietary restrictions or allergies. The platform analyzes and connects millions of data points using AI and deep learning to understand user preference and make smarter, healthier recommendations, making it easy to find and trust the best, nutritionally tailored recipe and then shop for the ingredients in-store or online.
Whisk was signed posted to the funding opportunity by the West Midlands Academy Health Science Network (WMAHSN), the regional hub for innovation, digital health and wealth creation, facilitating collaborations between key partners to bring about solutions and better outcomes for patients. Whisk’s solution was selected from 116 entries that were submitted to the challenge from 25 countries. The platform will expand into the management of type 2 diabetes and will provide personalized nutritional support. Whisk will receive €100,000 to build and pilot the new functionality for people with type 2 diabetes, and will work closely with Ascensia Diabetes Care to bring it to patients.
“Nutrition and food selection is a huge component of type 2 diabetes management. The panel of judges and I were hugely impressed by Whisk’s current tool and how they plan to develop it for people with type 2 diabetes.” said Michael Kloss, CEO and President of Ascensia Diabetes. “By helping people with type 2 diabetes find personalized and tailored meal recommendations that are based on their own blood glucose data and food preferences, we have the potential to empower millions of people with type 2 diabetes to make healthier choices with what they eat.”
The Whisk digital solution for Ascensia is being specifically developed to help people with type 2 diabetes make better nutritional choices. The aim is to create smarter food experiences to make healthy, informed meal selections, taking into account the many factors that influence both their diabetes and their food choices. The app will use blood sugar data to train Whisk’s AI to power personalised nutrition recommendations that support individual needs. Users will be able to see how their blood glucose readings react to specific foods, allowing them to build a tailored meal plan based on how foods affect their diabetes. The app will also expand to include convenience foods and menus at restaurants, providing a complete set of options for users.
“We are absolutely delighted to have been chosen as the winner of the Ascensia Diabetes Challenge. Type 2 diabetes has reached epidemic levels in recent years, and at Whisk we are excited to be building a solution that we feel can help support these patients,” said Nick Holzherr, Whisk Founder and CEO “ We hope that through our work with Ascensia Diabetes Care, we can help to change the way this condition is managed.”
Whisk’s core technology uses extensive food ontology known as the Food Genome™, incorporates and understands macro and micro-nutritional data, flavor compounds, store availability, price and promotions. Whisk’s Food Genome maps the world’s food ingredients, their relationships. their properties (nutrition, perishability, flavour, categories) and food purchase options. It’s a combination of this deep ontological understanding of food with massive data about user behaviour that drives accurate, smart results at scale.
For further information on Whisk’s smart food platform, please visit: https://whisk.com.
Whisk’s smart food platform enables frictionless food experiences by connecting the world’s recipes, products, and shopping choices using artificial intelligence and deep learning.
Whisk was founded in 2012 by Nick Holzherr and now partners with 8 major retailers & 20 recipe publishers worldwide. Whisk is currently available in the UK and US, and is integrated to some of the largest players in the food ecosystem including Walmart, Tesco and Amazon Fresh.
About Ascensia Diabetes Care:
Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.
Home to the world renowned CONTOUR® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.
For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
The West Midlands Academic Health Science Network (WMAHSN) leads, catalyses and drives co-operation, collaboration and productivity between academia, industry, health and care providers and commissioners, and citizens, and accelerates the adoption of innovation to generate continuous improvement in the region’s health and wealth.
This will be achieved in a collaborative environment in which member organisations are mutually supportive and in which the technology-rich West Midlands’ life sciences community is fully integrated and generating additional investment. Innovation will be spread at scale and pace regionally, nationally and internationally. WMAHSN, its partners and the public will celebrate the region’s success as a centre for innovation, health and wealth and become the first digitally-enabled health economy in England. The improved generation and adoption of innovation will benefit the economy by giving the region’s academic institutions and life sciences industry a competitive advantage.